The Impact Of Pharmaceutical Policies On Pharmaceutical Sales Patterns In Sweden And Japan.

【Methods】 Outcome measure; sales volume (DDD/ 1,000inhabitants and day, Quarterly) Selected drugs; ACE inhibitors (ACEs; ATC code C09A) Angiotensin IIantagonists (ARBs; ATC code C09C) Study periods; Jan, 2002 – Dec, 2012 Jan, 2002 – Mar, 2013 Data source; from the Swedish eHealth Agency (e-hälsomyndigheten) Drug sales data (by IMS Japan) Statistical analysis The time-series autoregressive-moving average (ARIMA) modelling with seasonal and interventions. 1. Forecast some models from outcome time series 2. Select an ARIMA model most matched Using the BOX-Jenkins methodology 3. The selected model yields efficient estimates of the effect of interventions Intervention; A= patent expiry, B= new drug information This analysis was used SAS ver. 9.2 【Conclusion】 we found that the sales pattern of selected drugs were changed when new information on the medicines was launched and not by the patent expiry in Sweden. We didn’t find the phenomenon of switching of sales patter from candesartan to any drugs which had been well evaluated and was cheaper in Japan. Pharmaceutical policies in two countries, especially, restricted Swedish generic substitution and recommendation of generic substitution in Japan influences on this phenomenon and differences. The impact of pharmaceutical policies on pharmaceutical sales patterns in Sweden and Japan ☆ Shinobu Imai1), Kiyohide Fushimi2), Karolina Andersson Sundell3) 1)National Hospital Organization (Japan), 2)Tokyo Medical and Dental University (Japan), 3)Gothenburg University (Sweden)